Dorsey Wright & Associates Buys Shares of 472,814 Elanco Animal Health Incorporated $ELAN

Dorsey Wright & Associates acquired a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 472,814 shares of the company’s stock, valued at approximately $11,314,000. Elanco Animal Health makes up approximately 1.4% of Dorsey Wright & Associates’ investment portfolio, making the stock its 22nd biggest holding.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bessemer Group Inc. lifted its position in shares of Elanco Animal Health by 33.2% during the first quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock valued at $50,000 after buying an additional 525 shares during the last quarter. Jag Capital Management LLC grew its position in shares of Elanco Animal Health by 38.0% in the 1st quarter. Jag Capital Management LLC now owns 16,522 shares of the company’s stock worth $395,000 after buying an additional 4,548 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in shares of Elanco Animal Health during the 1st quarter worth approximately $66,390,000. Illinois Municipal Retirement Fund raised its stake in shares of Elanco Animal Health by 49.5% during the 1st quarter. Illinois Municipal Retirement Fund now owns 77,279 shares of the company’s stock worth $1,849,000 after acquiring an additional 25,585 shares in the last quarter. Finally, Geneos Wealth Management Inc. lifted its position in Elanco Animal Health by 3,358.1% during the first quarter. Geneos Wealth Management Inc. now owns 202,747 shares of the company’s stock valued at $4,852,000 after acquiring an additional 196,884 shares during the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Insider Buying and Selling at Elanco Animal Health

In related news, CEO Jeffrey N. Simmons purchased 4,971 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The stock was bought at an average price of $20.09 per share, with a total value of $99,867.39. Following the acquisition, the chief executive officer owned 171,971 shares in the company, valued at $3,454,897.39. The trade was a 2.98% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Rajeev A. Modi acquired 4,911 shares of the business’s stock in a transaction on Friday, May 15th. The shares were purchased at an average price of $20.35 per share, with a total value of $99,938.85. Following the completion of the purchase, the insider owned 160,812 shares in the company, valued at $3,272,524.20. This represents a 3.15% increase in their position. The SEC filing for this purchase provides additional information. 1.14% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ELAN. Citigroup raised their price objective on Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Wall Street Zen downgraded Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. JPMorgan Chase & Co. boosted their price target on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Weiss Ratings downgraded shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 11th. Finally, TD Cowen increased their price objective on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.55.

Elanco Animal Health Stock Down 0.4%

Elanco Animal Health stock opened at $25.84 on Friday. The firm has a market cap of $12.91 billion, a price-to-earnings ratio of -51.68, a price-to-earnings-growth ratio of 1.70 and a beta of 1.68. Elanco Animal Health Incorporated has a 52 week low of $13.39 and a 52 week high of $27.72. The business’s 50-day moving average price is $23.63 and its 200 day moving average price is $23.89. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.06. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The firm had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.28 billion. During the same period in the previous year, the firm earned $0.37 EPS. The business’s quarterly revenue was up 14.9% on a year-over-year basis. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, sell-side analysts anticipate that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current year.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.